Management of toxicities and optimal dosing of targeted drugs in advanced kidney cancer Academic Article uri icon

abstract

  • The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.

publication date

  • January 1, 2009